Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.54 |
| ▸ | FPR2 | P25090 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18234085 | 0.86 | SCN9A (0.53) | SCN9AFPR2LMNAMAPTADORA3 | |
| SCHEMBL16845408 | 0.84 | SCN9A (0.58) | SCN9AFPR2LMNA | |
| SCHEMBL21944871 | 0.82 | ADORA3 (0.60) | SCN9AFPR2MAPTADORA3 | |
| SCHEMBL16158907 | 0.81 | SCN9A (0.80) | SCN9AFPR2 | |
| SCHEMBL6394758 | 0.77 | LMNA (0.51) | LMNAMAPT | |
| SCHEMBL985111 | 0.76 | LMNA (0.54) | LMNAMAPT | |
| SCHEMBL1782842 | 0.74 | LMNA (0.69) | LMNAMAPT | |
| SCHEMBL19956170 | 0.74 | SCN9A (0.76) | SCN9AFPR2 | |
| SCHEMBL2616101 | 0.74 | LMNA (0.50) | LMNAMAPTADORA3 | |
| SCHEMBL19286915 | 0.74 | SCN9A (0.53) | SCN9AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083606-B1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-10-28 | — | — | EP | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2016-11-17 | — | — | US | disclosed |
| WO-2015094443-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | ADORA2B, P2RX2, P2RX3 | SCN9A 236/4885FPR2 486/4885LMNA 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.